ANTH SEC Filings - Anthera Pharmaceuticals, Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

LEI	549300Z72RGRIU8IX311
CIK	1316175

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Anthera Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

July 30, 2018	15-12B	ANTH / Anthera Pharmaceuticals, Inc. 15-12B 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-34637 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant a
July 20, 2018	S-8 POS	ANTH / Anthera Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on July 20, 2018 Registration No.
July 20, 2018	S-8 POS	ANTH / Anthera Pharmaceuticals, Inc. S-8 POS S-8 POS 1 d562835ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 20, 2018 Registration No. 333-165714 Registration No. 333-168970 Registration No. 333-172100 Registration No. 333-180144 Registration No. 333-188679 Registration No. 333-196740 Registration No. 333-213956 Registration No. 333-218420 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 2054
July 20, 2018	RW	ANTH / Anthera Pharmaceuticals, Inc. RW RW July 20, 2018 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Anthera Pharmaceuticals, Inc. Request for Withdrawal on Form RW Pursuant to Rule 477 of the United States Securities Act of 1933, as amended, of the Registration Statement on Form S-3 Filed on March 6, 2018 (File No. 333-223474). Ladies and Gentlemen: Pursuant to Rule 477 promulgated un
July 20, 2018	S-8 POS	ANTH / Anthera Pharmaceuticals, Inc. S-8 POS S-8 POS 1 d562835ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 20, 2018 Registration No. 333-165714 Registration No. 333-168970 Registration No. 333-172100 Registration No. 333-180144 Registration No. 333-188679 Registration No. 333-196740 Registration No. 333-213956 Registration No. 333-218420 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 2054
July 20, 2018	S-8 POS	ANTH / Anthera Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on July 20, 2018 Registration No.
July 20, 2018	S-8 POS	ANTH / Anthera Pharmaceuticals, Inc. S-8 POS S-8 POS 1 d562835ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 20, 2018 Registration No. 333-165714 Registration No. 333-168970 Registration No. 333-172100 Registration No. 333-180144 Registration No. 333-188679 Registration No. 333-196740 Registration No. 333-213956 Registration No. 333-218420 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 2054
July 20, 2018	S-8 POS	ANTH / Anthera Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on July 20, 2018 Registration No.
July 20, 2018	S-8 POS	ANTH / Anthera Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on July 20, 2018 Registration No.
July 20, 2018	S-8 POS	ANTH / Anthera Pharmaceuticals, Inc. S-8 POS S-8 POS 1 d562835ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 20, 2018 Registration No. 333-165714 Registration No. 333-168970 Registration No. 333-172100 Registration No. 333-180144 Registration No. 333-188679 Registration No. 333-196740 Registration No. 333-213956 Registration No. 333-218420 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 2054
July 20, 2018	POS AM	ANTH / Anthera Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on July 20, 2018 Registration No.
July 20, 2018	POS AM	ANTH / Anthera Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on July 20, 2018 Registration No.
July 20, 2018	POS AM	ANTH / Anthera Pharmaceuticals, Inc. POS AM POS AM 1 d564668dposam.htm POS AM As filed with the Securities and Exchange Commission on July 20, 2018 Registration No. 333-172637 Registration No. 333-175095 Registration No. 333-179043 Registration No. 333-187771 Registration No. 333-187780 Registration No. 333-210166 Registration No. 333-221532 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO.
July 20, 2018	POS AM	ANTH / Anthera Pharmaceuticals, Inc. POS AM POS AM 1 d564668dposam.htm POS AM As filed with the Securities and Exchange Commission on July 20, 2018 Registration No. 333-172637 Registration No. 333-175095 Registration No. 333-179043 Registration No. 333-187771 Registration No. 333-187780 Registration No. 333-210166 Registration No. 333-221532 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO.
July 20, 2018	POS AM	ANTH / Anthera Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on July 20, 2018 Registration No.
July 20, 2018	POS AM	ANTH / Anthera Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on July 20, 2018 Registration No.
July 20, 2018	POS AM	ANTH / Anthera Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on July 20, 2018 Registration No.
July 17, 2018	25	ANTH / Anthera Pharmaceuticals, Inc. 25 25 1 p717180form25.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-34637 ANTHERA PHARMACEUTICALS, INC. The NASDAQ Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security
July 9, 2018	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 6, 2018 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Commiss
July 9, 2018	EX-99.1	Anthera Pharmaceuticals Announces SEC Deregistration Exhibit 99.1 Anthera Pharmaceuticals Announces SEC Deregistration HAYWARD, Calif., July 9, 2018 - Anthera Pharmaceuticals, Inc. (OTC: ANTH) (“Anthera”) or the “Company”) announced today that in order to complete the expected delisting of its common stock, the Company intends to file a Form 25 (Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange A
June 27, 2018	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits 8-K 1 g6271818k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 27, 2018 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of in
June 27, 2018	EX-99.1	Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets HAYWARD, Calif., June 27, 2018 - Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) (“Anthera” or the “Company”) announced today that it has withdrawn its request for a hearing to appeal the delisting determinat
June 18, 2018	EX-10.1	Letter Agreement between Anthera Pharmaceuticals, Inc. and Craig Thompson, dated June 15, 2018. Exhibit 10.1 ANTHERA PHARMACEUTICALS, INC. June 15, 2018 PERSONAL AND CONFIDENTIAL J. Craig Thompson Re: Adjustment to Terms of Employment; Notice of Termination Dear Craig: This letter agreement memorializes the mutual agreement between you and Anthera Pharmaceuticals, Inc. (the “Company”) regarding your continued employment with the Company. Except as provided herein, the terms of your Amended a
June 18, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 m6171808k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2018 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorp
May 30, 2018	8-K	Other Events 8-K 1 p5301818k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 30, 2018 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of inc
May 23, 2018	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 22, 2018 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Commiss
May 15, 2018	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934P For the transition period from to Commission file number: 001-34637 ANTHERA
April 16, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Costs Associated with Exit or Disposal Activities 8-K 1 p4161818k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2018 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incor
March 23, 2018	CORRESP	ANTH / Anthera Pharmaceuticals, Inc. CORRESP CORRESP 1 filename1.htm Anthera Pharmaceuticals, Inc. 25801 Industrial Boulevard, Suite B Hayward, California 94545 March 23, 2018 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Anthera Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-223474 Request for Acceleration Ladies and Gentlemen: Pursuant to Ru
March 12, 2018	EX-99.1	Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura - Sollpura did not achieve the primary endpoint of the coefficient of fat absorption (“CFA”) - Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (“CNA”) - Further development of Sollpura to be discontinued - Anthera to evalua
March 12, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K 1 d3121818k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2018 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incor
March 6, 2018	S-3	ANTH / Anthera Pharmaceuticals, Inc. S-3 S-3 1 d454676ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on March 6, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-1852016 (State or other ju
March 5, 2018	EX-99.1	Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial Results Exhibit 99.1 Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial Results · RESULT study reported positive interim futility analyses and completion of dosing, with top line data expected in March 2018 · Completed private placement for net proceeds of $13.3 million · Received net proceeds of $3.1 million from warrant exercises and sale of shares
March 5, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 j351808k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2018 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorpo
March 5, 2018	10-K	ANTH / Anthera Pharmaceuticals, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34637 ANTHERA PHARMA
March 5, 2018	EX-10.37	Employment Agreement by and between the Company and William Shanahan, M.D., dated January 5, 2018. Exhibit 10.37 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 5th day of January, 2018, between Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and William Shanahan (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms contained herein. NOW, THEREFORE, in con
March 5, 2018	EX-10.41	Termination of Pleasanton Office lease, dated February 28, 2018 Exhibit 10.41 TERMINATION OF LEASE AGREEMENT THIS TERMINATION OF LEASE AGREEMENT (the “Agreement”) is dated as of February , 2018 (“Effective Date”), and is made by and between HACIENDA INSPIRATION, LLC, a California limited liability company (“Landlord”), having an office at P.O. Box 2865, Dublin, California 94568, and ANTHERA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”), having an of
March 5, 2018	EX-10.36	Amended and Restated Employment Agreement by and between the Company and May Liu, dated January 5, 2018 Exhibit 10.36 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 5th day of January, 2018, between Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and May Liu (the “Executive”). WHEREAS, the Company desires to amend the Employment Agreement by and between the Company and the Executive, dated as of January 25, 2016, and the Exe
March 5, 2018	EX-10.39	Employment Agreement by and between the Company and Patrick Murphy, dated January 5, 2018. Exhibit 10.39 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 5th day of January, 2018, between Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Patrick Murphy (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms contained herein. NOW, THEREFORE, in consi
March 5, 2018	EX-10.35	Amended and Restated Employment Agreement by and between the Company and Craig Thompson, dated January 5, 2018 Exhibit 10.35 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 5th day of January, 2018, between Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Craig Thompson (the “Executive”). WHEREAS, the Company desires to amend the Employment Agreement by and between the Company and the Executive, dated as of January 25, 2016, and
March 5, 2018	EX-10.38	Employment Agreement by and between the Company and Renee Martin, Ph.D., dated January 5, 2018. Exhibit 10.38 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 5th day of January, 2018, between Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Renee Martin, Ph.D. (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms contained herein. NOW, THEREFORE, in
February 22, 2018	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / 683 Capital Management, LLC - FEBRUARY 22, 2018 Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* Anthera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03674U300 (CUSIP Number) January 8, 2018 (Date of Eve
February 14, 2018	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / Frigate Ventures LP - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Rule 13d-102) (Amendment No.
February 14, 2018	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 2 TO THE SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga20742203102142018.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Anthera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0
February 5, 2018	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 anth17a3.htm CUSIP NO. 03674U300 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ANTHERA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03674U300 (CUSIP Number) December 31, 2017 (Date of Event Which Requires F
January 25, 2018	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2018 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commiss
January 25, 2018	EX-99.1	Anthera Receives Positive Nasdaq Listing Determination Exhibit 99.1 Anthera Receives Positive Nasdaq Listing Determination Hayward, Calif., January 25, 2018 - Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that on January 24, 2018, Anthera received formal notice that the Nasdaq Hearings Panel granted Anthera?s request for inclusion on The Nasdaq Capital Market. Anthera?s continued listing on The Nasdaq Capital Market is subject to compli
January 18, 2018	SC 13G	ANTH / Anthera Pharmaceuticals, Inc. / 683 Capital Management, LLC - JANUARY 18, 2018 Passive Investment SC 13G 1 anthera13g-011818.htm JANUARY 18, 2018 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No.)* Anthera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03674U3
January 9, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2018 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commissi
January 9, 2018	EX-99.1	Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering Exhibit 99.1 Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering HAYWARD, Calif., January 9, 2018 (GLOBE NEWSWIRE) - Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has completed the second closing of the private placement of its equity securities (?PIPE?) with certain institutional and accredited investors. The PIPE transaction was previo
December 4, 2017	DEF 14A	Amendment No. 3 to 2010 Employee Stock Purchase Plan(24) DEF 14A 1 d484656ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commi
November 30, 2017	CORRESP	ANTH / Anthera Pharmaceuticals, Inc. ESP CORRESP Goodwin Procter LLP Three Embarcadero Center 28th Floor San Francisco, CA 94111 November 30, 2017 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 29, 2017	424B4	28,613,474 Shares of Common Stock 424B4 1 d493190d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-221532 PROSPECTUS 28,613,474 Shares of Common Stock This prospectus relates to the resale from time to time of up to 28,613,474 shares of our common stock by the selling stockholders named in this prospectus. These shares consist of: • 2,306,737 shares of common stock issued to the selling stock
November 22, 2017	CORRESP	ANTH / Anthera Pharmaceuticals, Inc. ESP CORRESP Anthera Pharmaceuticals, Inc. 25801 Industrial Boulevard, Suite B Hayward, California 94545 November 22, 2017 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Anthera Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-221532 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promul
November 20, 2017	PRE 14A	ANTH / Anthera Pharmaceuticals, Inc. PRE 14A PRE 14A 1 d484656dpre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commi
November 17, 2017	EX-99.1	Anthera Pharmaceuticals Announces Expected Receipt of Nasdaq Listing Determination Notice and Plans Appeal Exhibit 99.1 Anthera Pharmaceuticals Announces Expected Receipt of Nasdaq Listing Determination Notice and Plans Appeal ? Delisting notice was expected as part of the compliance extension previously granted by Nasdaq ? Continue ?ANTH? listing until formal hearing process is complete with the Nasdaq Hearings Panel HAYWARD, Calif., November 17, 2017 - Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) ann
November 17, 2017	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 14, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Co
November 13, 2017	S-3	ANTH / Anthera Pharmaceuticals, Inc. S-3 S-3 1 d493190ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on November 13, 2017. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Anthera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 20-1852016 (State or other juri
November 8, 2017	10-Q	ANTH / Anthera Pharmaceuticals, Inc. 10-Q (Quarterly Report) 10-Q 1 a103117010q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934P For the transition period from to Commission file
November 6, 2017	8-K	ANTH / Anthera Pharmaceuticals, Inc. (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commiss
November 6, 2017	EX-99.1	Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results EX-99.1 2 ex991.htm Exhibit 99.1 Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results o RESULT, Phase 3 clinical study of Sollpura, topline data expected Q1’2018 o RESULT sanctioned by the European Cystic Fibrosis Society Clinical Trial Network o Blisibimod granted FDA orphan drug designation for the treatment of IgA nephropathy o Executed a private pla
November 3, 2017	SC 13G	ANTH / Anthera Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
October 25, 2017	EX-10.3	Form of Warrant sold pursuant to that Securities Purchase Agreement, among the Company and the purchasers thereto, dated October 23, 2017 (14 EX-10.3 Exhibit 10.3 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE
October 25, 2017	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 d469259d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdict
October 25, 2017	EX-99.1	Anthera Pharmaceuticals Announces Pricing of $15 Million Private Placement Offering EX-99.1 Exhibit 99.1 Anthera Pharmaceuticals Announces Pricing of $15 Million Private Placement Offering HAYWARD, Calif., October 24, 2017 ? Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it has entered into a definitive agreement with certain institutional and accredited investors in connection with the private placement of its equity securities (? PIPE?). The PIPE is expected
October 25, 2017	EX-3.1	Certificate of Designation of Preferences, Rights and Limitations of Class Y Convertible Preferred Stock, dated October 24, 2017 EX-3.1 2 d469259dex31.htm EX-3.1 Exhibit 3.1 ANTHERA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF CLASS Y CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW ANTHERA PHARMACEUTICALS, INC., Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporatio
October 25, 2017	EX-10.1	Securities Purchase Agreement by and among the Company and the Purchasers party thereto, dated October 23, 2017(41 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 23, 2017 by and among Anthera Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). RECITALS A. The Company
October 25, 2017	EX-10.2	Registration Rights Agreement, by and among the Company and the Purchasers party thereto, dated October 23, 2017(42) EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of October 23, 2017, by and among Anthera Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and the several purchasers signatory hereto (each a ?Purchaser? and collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purchase Ag
September 22, 2017	10-Q/A	ANTH / Anthera Pharmaceuticals, Inc. AMENDMENT NO. 1 (Quarterly Report) 10-Q/A 1 p92217010qa1.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr
August 28, 2017	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commissi
August 28, 2017	EX-99.1	Anthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy Exhibit 99.1 Anthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy ? Trend toward preservation of renal function (eGFR) in blisibimod treated patients ? Lack of disease progression, as measured by proteinuria in blisibimod treated patients HAYWARD, Calif., August 28, 2017 (GLOBE NEWSWIRE) - Anthera Pharmaceutic
August 9, 2017	EX-99.1	Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy Exhibit 99.1 Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy HAYWARD, Calif., August 9, 2017 (GLOBE NEWSWIRE) ? Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that blisibimod has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Immunoglobulin A nephropathy (IgAN). Blisibimod targets B-cel
August 9, 2017	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commissio
August 9, 2017	EX-99.1	Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results o RESULT, pivotal Phase 3 study of Sollpura began screening patients in the U.S. and Europe o RESULT study approved by the Cystic Fibrosis Foundation Therapeutics Development Network o BRIGHT, Phase 2 study of blisibimod in IgA Nephropathy remains on trac
August 9, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commissio
August 9, 2017	EX-10.2	Sublease Agreement by and between the Company and NewRT, dated as of July 20, 2017 Exhibit 10.2 BASIC SUBLEASE TERMS Sublandlord: NewRT Medical Systems, Inc., a Delaware corporation Subtenant: Anthera Pharmaceuticals, a Delaware corporation Landlord: MEPT Mount Eden LLC, a Delaware limited liability company Prime Lease: That certain Triple Net Lease dated as of July 20, 2017 (“Prime Lease”) between Sublandlord and Landlord for the leasing of approximately 14,034 rentable square
August 9, 2017	10-Q	ANTH / Anthera Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34637 ANTHERA PH
July 14, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commission
July 11, 2017	SC 13G/A	Anthera Pharmaceuticals SC 13G/A (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Anthera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03674U300 (CUSIP Number) March 17, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
June 19, 2017	8-K	Anthera Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (C
June 19, 2017	EX-1.1	Purchase Agreement between the Company and Lincoln Park Capital Fund, LLC, dated June 19, 2017(39) EX-1.1 Exhibit 1.1 EXECUTION VERSION PURCHASE AGREEMENT PURCHASE AGREEMENT (the ?Agreement?), dated as of June 19, 2017, by and between ANTHERA PHARMACEUTICALS, INC., a Delaware corporation, (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell
June 19, 2017	424B5	$10,300,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-210166 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2016) $10,300,000 Common Stock This prospectus supplement relates to the issuance and sale of up to $10,300,000 in shares of our common stock to Lincoln Park Capital Fund, LLC, or Lincoln Park, under a Purchase Agreement entered into on June 19, 2017, or the Pur
June 19, 2017	424B5	Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-210166 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 18, 2016) Common Stock This prospectus supplement amends, supplements and supersedes our prospectus supplement dated April 21, 2016 and its accompanying prospectus dated April 18, 2016 related to our sales agreement dated April 21, 2016, with H.C. Wainwright & Co.,
June 9, 2017	S-8 POS	Anthera Pharmaceuticals POST- EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As filed with the Securities and Exchange Commission on June 9, 2017 Registration No.
June 9, 2017	AW	Anthera Pharmaceuticals June 9, 2017 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Anthera Pharmaceuticals, Inc. Request for Withdrawal Pursuant to Rule 477 of Post-Effective Amendment No. 1 to Form S-8 filed under form type POS AM (File No. 333-218420) Ladies and Gentlemen: On behalf of Anthera Pharmaceuticals, Inc. (the ?Company?), we hereby submit this letter to notify
June 9, 2017	AW WD	Anthera Pharmaceuticals D AW WD 1 j69170awwd.htm June 9, 2017 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Anthera Pharmaceuticals, Inc. Request for Withdrawal of Form AW (File No. 333-218420) Ladies and Gentlemen: Anthera Pharmaceuticals, Inc. (the “Company”), hereby respectfully requests that the Securities and Exchange Commission (the “SEC”) consent to the withdrawal, e
June 8, 2017	AW	Anthera Pharmaceuticals Goodwin Procter LLP Three Embarcadero Center 28 th Floor San Francisco, CA 94111 goodwinlaw.
June 5, 2017	POS AM	Anthera Pharmaceuticals AM As filed with the Securities and Exchange Commission on June 5, 2017 Registration No.
June 1, 2017	S-8	Anthera Pharmaceuticals As filed with the Securities and Exchange Commission on June 1, 2017 Registration No.
May 25, 2017	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 22, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Commiss
May 18, 2017	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 15, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Commiss
May 10, 2017	EX-99.1	Anthera Pharmaceuticals Provides Business Update and Reports 2017 First Quarter Financial Results Exhibit 99.1 Anthera Pharmaceuticals Provides Business Update and Reports 2017 First Quarter Financial Results o RESULT, pivotal Phase 3 Study of Sollpura, is expected to screen the first patient in May o Favorable trends on weight, height, and body mass index (?BMI?) from the Extension Period of the SOLUTION Study of Sollpura o Completion of dosing in the Phase 2 BRIGHT-SC Study of blisbimod in p
May 10, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commission
May 10, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34637 ANTHERA P
May 10, 2017	EX-3.1	CERTIFICATE OF AMENDMENT FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ANTHERA PHARMACEUTICALS, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANTHERA PHARMACEUTICALS, INC. Craig Thompson hereby certifies that: ONE: The date of filing the original Certificate of Incorporation of Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”) with the Secretary of State of the State of Delaware was September 9, 2004. TWO: He is the
April 28, 2017	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commissio
April 28, 2017	EX-3.1	Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation filed April 28, 2017 EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANTHERA PHARMACEUTICALS, INC. Craig Thompson hereby certifies that: ONE: The date of filing the original Certificate of Incorporation of Anthera Pharmaceuticals, Inc., a Delaware corporation (the ?Corporation?) with the Secretary of State of the State of Delaware was September 9, 2004. TWO: He is the
April 28, 2017	EX-99.1	Anthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock EX-99.1 3 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Anthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) announced today that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-8 reverse stock split of its common stock, effective as of April 28, 2017 at 5:00 p.m. Eastern Time. A Certi
April 27, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commissio
March 30, 2017	EX-99.1	Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura EX-99.1 2 d257229dex991.htm EX-99.1 Exhibit 99.1 Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura • Sollpura demonstrated comparable maintenance in key measurements of height, weight, and BMI • Sollpura was well tolerated throughout the 20-Week Extension Period HAYWARD, California, March 29, 2017 — Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today ann
March 30, 2017	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commi
March 20, 2017	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d330126dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, 0.001 par value, of Anthera Pharmaceuticals, Inc., a Delaware co
March 20, 2017	SC 13G	ANTH / Anthera Pharmaceuticals, Inc. / Frigate Ventures LP - SC 13G Passive Investment SC 13G 1 d330126dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Anthera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, 0.001 par value (Title of Class of Securities) 03674U201 (CUSIP Number) March 1
March 16, 2017	DEFA14A	Anthera Pharmaceuticals 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of
March 16, 2017	DEF 14A	Anthera Pharmaceuticals 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of
March 16, 2017	EX-4.1	Form of Tranche 1 Warrant (filed as Exhibit 4.1 to the registrant’s Form 8-K filed with the SEC on March 16, 2017 and incorporated herein by reference). EX-4.1 Exhibit 4.1 [FORM OF WARRANT ? 5 YEAR TRANCHE] THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT. ANTHERA PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: Date of Issuance: March [17], 2017 (?Issuance Date?) CUSIP: [ ] Anthera Pharmaceuticals, Inc.,
March 16, 2017	8-K	Anthera Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commi
March 16, 2017	EX-99.1	Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants EX-99.1 Exhibit 99.1 Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants HAYWARD, Calif., March 13, 2017 ? Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) (the ?Company?) today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. In addition, the Company intend
March 16, 2017	EX-10.1	Amendment to At Market Issuance Sales Agreement between the Company and H.C. Wainwright & Co., LLC, dated March 14, 2017(38) EX-10.1 6 d362679dex101.htm EX-10.1 Exhibit 10.1 H.C. Wainwright & Co., LLC 430 Park Avenue, 4th Floor New York, New York 10022 March 14, 2017 Ladies and Gentlemen: Pursuant to the terms and subject to the conditions contained in the at the Market Offering Sales Agreement between Anthera Pharmaceuticals, Inc. (the “Company”), and H.C. Wainwright & Co., LLC (“Wainwright”) dated April 21, 2016 (the
March 16, 2017	EX-4.2	[FORM OF WARRANT –6 MONTH TRANCHE] EX-4.2 Exhibit 4.2 [FORM OF WARRANT ?6 MONTH TRANCHE] THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT. ANTHERA PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: Date of Issuance: March [17], 2017 (?Issuance Date?) CUSIP: [ ] Anthera Pharmaceuticals, Inc.,
March 16, 2017	EX-99.2	Anthera Pharmaceuticals Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants EX-99.2 Exhibit 99.2 Anthera Pharmaceuticals Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants HAYWARD, Calif., March 14, 2017 ? Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) (the ?Company?) today announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a price of $0.50 per share and two tranches of warrants to purchase an ag
March 16, 2017	EX-1.1	30,000,000 Shares of Common Stock ($0.001 Par Value) Warrants to Purchase up to 60,000,000 Shares of Common Stock Anthera Pharmaceuticals, Inc. Common Stock EQUITY UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 30,000,000 Shares of Common Stock ($0.001 Par Value) and Warrants to Purchase up to 60,000,000 Shares of Common Stock Anthera Pharmaceuticals, Inc. Common Stock EQUITY UNDERWRITING AGREEMENT March 14, 2017 H.C. Wainwright & Co., LLC As Representative of the several Underwriters 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Anthera Pharmaceuticals, Inc., a Delaware cor
March 16, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34637 ANTHERA PHARMA
March 16, 2017	EX-10.43	December 6, 2016 Exhibit 10.43 December 6, 2016 Dear Craig: The purpose of this letter is to document your appointment to serve as the Company’s President and Chief Executive Officer (CEO): 1. Position. Effective December 6, 2016, your new title is President and CEO, reporting directly to the Executive Chairman of the Board. 2. Compensation. The Company will compensate you at the rate of $460,000 per annum. In add
March 15, 2017	424B5	30,000,000 Shares of Common Stock Warrants to Purchase 60,000,000 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-210166 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2016) 30,000,000 Shares of Common Stock Warrants to Purchase 60,000,000 Shares of Common Stock We are offering 30,000,000 shares of our common stock together with two tranches of warrants to purchase an aggregate of 60,000,000 shares of our common stock. This pr
March 13, 2017	424B5	Subject to Completion, Dated March 13, 2017 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-210166 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompany
February 27, 2017	EX-99.1	Anthera Pharmaceuticals Provides Business Update and Reports 2016 Fourth Quarter and Fiscal Year Financial Results Exhibit 99.1 Anthera Pharmaceuticals Provides Business Update and Reports 2016 Fourth Quarter and Fiscal Year Financial Results o SOLUTION study with Sollpura™ missed non-inferiority endpoint by 1%, prompting new phase 3 study o Data Monitoring Committee issued recommendation to continue SIMPLICITY study with Sollpura™ o Blisibimod for the treatment of IgA Nephropathy demonstrated positive trends
February 27, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commis
February 24, 2017	PRE 14A	Anthera Pharmaceuticals 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement o Confidential, for Use of
February 16, 2017	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 10, 2017 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Co
February 14, 2017	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga10742203102142017.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Anthera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0
February 9, 2017	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 anth16a2.htm CUSIP NO. 03674U201 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ANTHERA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03674U201 (CUSIP Number) December 31, 2016 (Date of Event Which Requires F
January 6, 2017	8-K	Anthera Pharmaceuticals (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 31, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Co
December 27, 2016	EX-99.1	Anthera Announces the Phase 3 SOLUTION Study with Sollpura™ in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results – Additional Study Needed Exhibit 99.1 Anthera Announces the Phase 3 SOLUTION Study with Sollpura? in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results ? Additional Study Needed ? Sollpura narrowly missed the primary endpoint for change in the Coefficient of Fat Absorption (CFA) non-inferiority margin ? Sollpura demonstrated non-inferiority in the per protocol CFA analysis ? S
December 27, 2016	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 27, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Co
December 6, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 2, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Com
December 6, 2016	EX-99.1	Anthera Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of blisibimod for IgA Nephropathy Exhibit 99.1 Anthera Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of blisibimod for IgA Nephropathy ? J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of Directors ? Paul F. Truex appointed as Executive Chairman of the Board ? Dr. Christopher Henney stepped down as Chairman of the Board but will remain as Dir
December 1, 2016	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 28, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Co
November 10, 2016	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 10, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Co
November 10, 2016	EX-99.1	Anthera Announces that the Blisibimod CHABLIS-SC1 Phase 3 Study Did Not Achieve the Primary Endpoint in Patients with Active Systemic Lupus Erythematosus Exhibit 99.1 Anthera Announces that the Blisibimod CHABLIS-SC1 Phase 3 Study Did Not Achieve the Primary Endpoint in Patients with Active Systemic Lupus Erythematosus - Assessing next steps for blisibimod for the treatment of Systemic Lupus Erythematosus - Continuing to explore blisibimod as treatment for IgA nephropathy ? Phase 2 data in December - Sollpura TMSOLUTION phase 3 study in exocrine pa
November 7, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34637 ANTHE
November 7, 2016	EX-10.4	William Shanahan, M.D Exhibit 10.4 William Shanahan, M.D Re: Offer of Employment Dear Bill: Anthera Pharmaceuticals, Inc. (the “Company”) is pleased to extend to you an offer of employment with the Company, as follows: 1. Position. The Company will employ you in the position of Chief Medical Officer (CMO) reporting to the Company’s President & COO. Your employment will commence on or about September 1, 2016. 2. Compens
November 4, 2016	EX-99.1	Anthera Pharmaceuticals Provides Business Update and Reports 2016 Third Quarter Financial Results Exhibit 99.1 Anthera Pharmaceuticals Provides Business Update and Reports 2016 Third Quarter Financial Results ? Blisibimod topline data from the Phase 3 CHABLIS-SC1 Study in severe lupus patients is imminent ? Data and Safety Monitoring Board recommendation to continue SOLUTION study with Sollpura? ? FDA Type C meeting in September validated basis for BLA filing and manufacturing approach for Sol
November 4, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commiss
October 4, 2016	S-8	Anthera Pharmaceuticals S-8 S-8 1 d239336ds8.htm S-8 As filed with the Securities and Exchange Commission on October 4, 2016 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-1852016 (State or Other Jurisdiction of Incorporation or Orga
September 16, 2016	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated September 16, 2016 with respect to the shares of Common Stock of Anthera Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(
September 16, 2016	SC 13G	ANTH / Anthera Pharmaceuticals, Inc. / Biotechnology Value Fund L P - THE SCHEDULE 13G Passive Investment SC 13G 1 sc13g074220ant09162016.htm THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Anthera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title o
September 15, 2016	EX-3.1	Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock filed on September 15, 2016 EX-3.1 Exhibit 3.1 ANTHERA PHARMACEUTICALS, INC. AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW ANTHERA PHARMACEUTICALS, INC., Delaware corporation (the ?Corporation?), in accordance with the provisions of Section 103 of the Delaware General Corporation La
September 15, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 13, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (C
September 12, 2016	8-K	Anthera Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 6, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation)
September 12, 2016	EX-3.1	ANTHERA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS SERIES X CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW EX-3.1 Exhibit 3.1 ANTHERA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW ANTHERA PHARMACEUTICALS, INC., Delaware corporation (the ?Corporation?), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the ?DGCL?) does h
September 12, 2016	EX-4.1	Form of Warrant sold pursuant to that Securities Purchase Agreement, among the Company and the purchasers thereto, dated October 21, 2017 EX-4.1 Exhibit 4.1 WARRANT AGREEMENT To Purchase Shares of the Common Stock of ANTHERA PHARMACEUTICALS, INC. Dated as of September 12, 2016 (the ?Effective Date?) Anthera Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, [Name ], a [State][Type of Entity] (each, a ?Warrantholder?) is entitled, upon the terms and subject to th
September 12, 2016	EX-10.1	Subscription Agreement between the Company and Anthera Pharmaceuticals, Inc. and purchasers affiliated with Biotechnology Value Fund, L.P. and Rock Springs Capital Master Fund LP, dated September 6, 2016 (37) EX-10.1 7 d234580dex101.htm EX-10.1 Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is dated September 6, 2016, among Anthera Pharmaceuticals, Inc. a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its permitted successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, sub
September 12, 2016	EX-99.1	Anthera Pharmaceuticals Announces Initial $17.0 Million Closing of a Potential $45.33 Million Registered Direct Offering to Biotechnology Value Fund and Rock Springs Capital EX-99.1 Exhibit 99.1 Anthera Pharmaceuticals Announces Initial $17.0 Million Closing of a Potential $45.33 Million Registered Direct Offering to Biotechnology Value Fund and Rock Springs Capital HAYWARD, Calif., September 8, 2016 ? Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it has agreed to sell preferred convertible stock in two tranches to Biotechnology Value Fund, L.P. an
September 12, 2016	EX-4.2	Specimen Series X Convertible Preferred Stock certificate EX-4.2 Exhibit 4.2 NUMBER SHARES Anthera INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE AUTHORIZED: 17,000 SERIES X CONVERTIBLE PREFERRED SHARES, $0.001 PAR VALUE PER SHARE SEE REVERSE FOR CERTAIN DEFINITIONS This Certifies That is the owner of Fully Paid and Non-Assessable Series X Convertible Preferred Stock, $0.001 Par Value of ANTHERA PHARMACEUTICALS, INC. transferable on the books of th
September 12, 2016	EX-3.2	Form of Certificate of Designation of Preferences, Rights and Limitations of Series X-1 Convertible Preferred Stock filed on September 12, 2016 Exhibit 3.2 ANTHERA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X-1 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW ANTHERA PHARMACEUTICALS, INC., Delaware corporation (the Corporation), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the DGCL) does hereby
September 8, 2016	424B5	17,000 Shares Series X Convertible Preferred Stock 28,330 Shares Series X-1 Convertible Preferred Stock Warrants to Purchase up to $4,250,000 in Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-210166 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2016) 17,000 Shares Series X Convertible Preferred Stock 28,330 Shares Series X-1 Convertible Preferred Stock Warrants to Purchase up to $4,250,000 in Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering (i) 17
August 16, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Comm
August 16, 2016	EX-99.1	Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer Exhibit 99.1 Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer Hayward CA, August 16, 2016 ? Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of William Shanahan, M.D., J.D. as Chief Medical Officer. In his role as Chief Medical Officer, Dr. Shanahan will bring his experience as a Rheumatologist and drug development to lea
August 16, 2016	EX-24	EX-24 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of, May Liu, Paul F.
August 16, 2016	EX-24	EX-24 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of, May Liu, Paul F.
August 9, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commissio
August 9, 2016	EX-99.1	Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results · Met enrollment target in SOLUTION study and enrolled first patient in SIMPLICITY study of Sollpura™ · Successful sachet manufacturing to support SIMPLICITY study and commercial-scale lipase demonstration batch · First patient enrolled in pivotal CHABLIS
August 9, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34637 ANTHERA PH
June 29, 2016	8-K	Anthera Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (C
June 29, 2016	EX-99.1	Anthera Provides Clinical Program Updates for Blisibimod and Sollpura EX-99.1 Exhibit 99.1 Anthera Provides Clinical Program Updates for Blisibimod and Sollpura? ? Positive trends from BRIGHT-SC proof-of-concept study - study to continue ? SOLUTION study with Sollpura completed patient screening ahead of schedule - data in 2016 ? First patients screened in Phase 3 CHABLIS 7.5 study of blisibimod in seropositive lupus patients ? CHABLIS-SC1 results to be reported in
May 10, 2016	EX-10.1	Employment Offer Letter, by and between the Company and Dr. James Pennington, dated as of April 1, 2016 (36) Exhibit 10.1 April 1, 2016 Dear Jim: The purpose of this letter is to document your appointment to serve as the Company’s Interim Chief Medical Officer (“Interim CMO): 1. Position. Effective April 1, 2016, your new title is Interim Chief Medical Officer, reporting directly to the Company’s President & Chief Operating Officer. 2. Compensation. The Company will compensate you at the rate of $360,000
May 10, 2016	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34637 ANTHERA P
April 29, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders p4281618k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporati
April 29, 2016	EX-99.1	Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors ex991.htm Exhibit 99.1 Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors Hayward, CA, April 27th, 2016 ? (GlobeNewswire) Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of Brent Furse to its Board of Directors. Mr. Furse has over 25 years of healthcare commercial leadership experience with extensive experience in the areas of sales and marketing, commer
April 29, 2016	EX-10.1	Anthera Pharmaceuticals, Inc. 25801 Industrial Boulevard, Suite B Hayward, California 94545 April 27, 2016 ex101.htm Exhibit 10.1 Anthera Pharmaceuticals, Inc. 25801 Industrial Boulevard, Suite B Hayward, California 94545 April 27, 2016 Lincoln Park Capital Fund, LLC 440 North Wells, Suite 410 Chicago, Illinois 60654 Dear Sirs: Reference is made to that certain Purchase Agreement, dated as of March 12, 2015 and as amended by letter dated July 8, 2015 (as so amended, the ?Purchase Agreement?), by and be
April 29, 2016	424B5	$14,389,500 Common Stock b428166424b5.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333- 210166 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2016) $14,389,500 Common Stock This prospectus supplement relates to the issuance and sale of up to $14,389,500 in shares of our common stock to Lincoln Park Capital Fund, LLC, or Lincoln Park, under a Purchase Agreement entered into on March 12, 2015, as amended on J
April 29, 2016	EX-24	EX-24 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Paul F.
April 22, 2016	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 m4211608k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incor
April 22, 2016	EX-10.1	ANTHERA PHARMACEUTICALS, INC. SALES AGREEMENT ex101.htm Exhibit 10.1 ANTHERA PHARMACEUTICALS, INC. $25,000,000 SALES AGREEMENT April 21, 2016 H.C. Wainwright & Co., LLC 430 Park Avenue, 4th Floor New York, New York 10022 Ladies and Gentlemen: Anthera Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as follows: 1. Issuance and Sale of Shares. The Company agrees tha
April 22, 2016	424B5	$25,000,000 Common Stock 424B5 1 l415160424b5.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-210166 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2016) $25,000,000 Common Stock We have entered into a sales agreement with H.C. Wainwright & Co., LLC, or H.C. Wainwright, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospectus.
April 20, 2016	10-K/A	Anthera Pharmaceuticals AMENDMENT NO. 1 (Annual Report) g42016110ka1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission
April 13, 2016	CORRESP	Anthera Pharmaceuticals ESP CORRESP Anthera Pharmaceuticals, Inc. 25801 Industrial Blvd, Suite B Hayward, CA 94545 VIA EDGAR April 13, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-4720 Attention: Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance Re: Anthera Pharmaceuticals, Inc. Acceleration Request for Registration Statement
March 17, 2016	DEFA14A	Anthera Pharmaceuticals 14A DEFA14A 1 s317160defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Stateme
March 15, 2016	DEFA14A	Anthera Pharmaceuticals 14A s315160defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confi
March 15, 2016	DEF 14A	Anthera Pharmaceuticals 14A s310161def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confid
March 14, 2016	S-3	Anthera Pharmaceuticals s310160s3.htm As filed with the Securities and Exchange Commission on March 14, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Anthera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2
March 14, 2016	EX-10.32	SUBSCRIPTION AGREEMENT EX-10.32 2 ex1032.htm EXHIBIT 10.32 Exhibit 10.32 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Subscription”) is dated August 14, 2015, by and between the investor identified on the signature page hereto (the “Investor”) and Anthera Pharmaceuticals, Inc., a company incorporated and registered in the State of Delaware (the “Company”). The Investor and the Company are parties to a Stock
March 14, 2016	EX-10.37	EMPLOYMENT AGREEMENT Exhibit 10.37 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 25th day of January, 2016, between Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Colin Hislop, M.D. (the “Executive”). WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the terms contained her
March 14, 2016	EX-10.36	EMPLOYMENT AGREEMENT Exhibit 10.36 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 25th day of January, 2016, between Anthera Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Craig Thompson (the ?Executive?). WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the terms contained herein.
March 14, 2016	EX-10.40	EMPLOYMENT AGREEMENT EX-10.40 10 ex1040.htm EXHIBIT 10.40 Exhibit 10.40 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 25th day of January, 2016, between Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and May Liu (the “Executive”). WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company
March 14, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34637 ANTHERA PHARMA
March 14, 2016	EX-10.33	Deferred Compensation Election Form by and between the Company and Paul Truex, effective as of December 28, 2015 (34) Exhibit 10.33 ANTHERA PHARMACEUTICALS, INC. Deferred Compensation Election Form I. Elective Deferral Percentages As specified below, I elect pursuant to the Deferred Compensation Agreement entered into by Anthera Pharmaceuticals, Inc. (the “Company”) and me as of the 28th day of December, 2015 (the “Deferred Compensation Agreement”) to defer receipt of that percentage of my Eligible Compensation w
March 14, 2016	EX-10.35	Employment Agreement, by and between the Company and Mr. Paul Truex, dated as of January 25, 2016 (35) Exhibit 10.35 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 25th day of January, 2016, between Anthera Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Paul F. Truex (the ?Executive?). WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the terms contained herein.
March 14, 2016	EX-10.39	EMPLOYMENT AGREEMENT Exhibit 10.39 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 25th day of January, 2016, between Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Chuck Olson, Ph.D. (the “Executive”). WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the terms contained her
March 14, 2016	EX-10.34	* * * * Exhibit 10.34 December 4, 2015 Re: Offer of Employment Dear Craig, Anthera Pharmaceuticals, Inc. (the “Company”) is pleased to extend to you an offer of employment with the Company, as follows: 1. Position. The Company will employ you in the position of President and Chief Operating Officer reporting to the Company’s Chief Executive Officer. Your employment will commence on or about January 7th, 2
March 14, 2016	EX-10.38	EMPLOYMENT AGREEMENT EX-10.38 8 ex1038.htm EXHIBIT 10.38 Exhibit 10.38 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 25th day of January, 2016, between Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Klara Dickinson-Eason (the “Executive”). WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by
March 10, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d3101608k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incor
March 10, 2016	EX-99.1	Anthera Pharmaceuticals Provides Business Update and Reports 2015 Fourth Quarter and Fiscal Year Financial Results ex991.htm Exhibit 99.1 Anthera Pharmaceuticals Provides Business Update and Reports 2015 Fourth Quarter and Fiscal Year Financial Results ? SOLUTION clinical study of oral Sollpura? enrollment to begin soon in Europe ? Data from BRIGHT-SC study in IgA nephropathy planned for Q2 2016 ? Addition of Craig Thompson as President and Chief Operating Officer ? Appointment of Dr. James Pennington to Inter
March 8, 2016	EX-99.1	Anthera Pharmaceuticals Announces Appointment of Dr. James Pennington as Interim Chief Medical Officer Unassociated Document Exhibit 99.1 Anthera Pharmaceuticals Announces Appointment of Dr. James Pennington as Interim Chief Medical Officer HAYWARD, Calif., March 07, 2016 (GLOBE NEWSWIRE) - Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of James Pennington, M.D. as interim Chief Medical Officer following the Company's acceptance of Colin Hislop's resignation effective A
March 8, 2016	8-K	Anthera Pharmaceuticals (Current Report/Significant Event) l371608k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorpora
February 17, 2016	8-K	Anthera Pharmaceuticals (Current Report/Significant Event) m2161628k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 12, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of inco
February 16, 2016	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 12, 2016	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / ProQuest Investments IV, L.P. - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No.
February 12, 2016	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / Broadfin Capital, LLC Passive Investment SC 13G/A 1 d703151713ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Anthera Pharmaceuticals, Inc. (Name of Issuer) common stock, par value $0.001 per share (Title of Class of Securities) 03674U201 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the
February 3, 2016	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 anth15a1.htm CUSIP NO. 03674U201 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ANTHERA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03674U201 (CUSIP Number) December 31, 2015 (Date of Event Which Requires F
February 3, 2016	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / Zenyaku Kogyo Co., Ltd. - SC 13G/A Passive Investment SC 13G/A 1 a16-29651sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Anthera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03674U201 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Stateme
January 29, 2016	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 25, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of incorporation) (Com
January 8, 2016	EX-99.1	Anthera Pharmaceuticals Announces Appointment of Craig Thompson as President and Chief Operating Officer and Dr. Chuck Olson as Chief Technology Officer ex99_1.htm Exhibit 99.1 Anthera Pharmaceuticals Announces Appointment of Craig Thompson as President and Chief Operating Officer and Dr. Chuck Olson as Chief Technology Officer HAYWARD, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) - Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the appointment of Craig Thompson as President and Chief Operating Officer. In this role Mr. Thompson will overse
January 8, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 j161628k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 5, 2016 ANTHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34637 20-1852016 (State or other jurisdiction of i
November 9, 2015	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34637 ANTHE
November 6, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commiss
November 6, 2015	EX-99.1	Anthera Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Anthera Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results · Closed $29 million public offering in July including full exercise of underwriters’ option to purchase additional shares · Completed capsule manufacturing in support of the SOLUTION clinical study · Initiated the SOLUTION clinical study of oral Sollpura™
September 14, 2015	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits j9141508k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorpor
September 14, 2015	EX-99.1	Anthera Announces Termination of Blisibimod Partnership in Japan by Zenyaku ex991.htm Exhibit 99.1 Anthera Announces Termination of Blisibimod Partnership in Japan by Zenyaku ? Anthera will regain all worldwide rights for blisibimod without cost ? No patients were enrolled in the BRIGHT-SC study or any other clinical study in Japan ? Zenyaku is required to continue various funding obligations during the termination period ? No effect on blisibimod lupus program or Sollpur
August 17, 2015	8-K	Anthera Pharmaceuticals (Current Report/Significant Event) l8131518k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporat
August 17, 2015	424B5	150,915 Shares Common Stock l813152424b5.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-187780 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2013) 150,915 Shares Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering an aggregate of 150,915 shares of our common stock directly to investors pursuant to a subscription agreement we entered into with an investor on A
August 10, 2015	EX-3.4	Amended and Restated Bylaws, as amended, of the Registrant Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF ANTHERA PHARMACEUTICALS, INC. (the ?Corporation?) As amended through May 21, 2015 ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Direc
August 10, 2015	EX-99.1	Anthera Pharmaceuticals Reports 2015 Second Quarter and Operational Update ex991.htm Exhibit 99.1 Anthera Pharmaceuticals Reports 2015 Second Quarter and Operational Update ? Reached enrollment target of 400 subjects in Phase 3 CHABLIS-SC1 clinical study with blisibimod ? Additional data on patient-reported outcomes from Phase 2b PEARL-SC blisibimod clinical study presented at EULAR ? Increased cash position by an incremental $27 million through public offering in July ?
August 10, 2015	EX-10.1	Anthera Pharmaceuticals, Inc. 25801 Industrial Boulevard, Suite B Hayward, California 94545 July 8, 2015 Exhibit 10.1 Anthera Pharmaceuticals, Inc. 25801 Industrial Boulevard, Suite B Hayward, California 94545 July 8, 2015 Lincoln Park Capital Fund, LLC 440 North Wells, Suite 410 Chicago, IL 60654 Dear Sirs: Reference is made to that certain Purchase Agreement (the ?Agreement?), dated as of March 12, 2015, by and between ANTHERA PHARMACEUTICALS, INC., a Delaware corporation, (the ?Company?), and LINC
August 10, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34637 ANTHERA PH
August 10, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 m891508k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incor
July 13, 2015	424B5	3,333,334 Shares Common Stock $7.50 per share 424B5 1 d943809d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-187780 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2013) 3,333,334 Shares Common Stock $7.50 per share We are selling 3,333,334 shares of our common stock in this offering. We have granted the underwriters an option for a period of 30 days to purchase up to an additional 500,000 shares
July 13, 2015	EX-99.2	Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock EX-99.2 5 d54024dex992.htm EX-99.2 Exhibit 99.2 Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock HAYWARD, Calif., July 9, 2015 /PRNewswire/ — Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock, offered at a price of $7.50 per share. The Company estimates that the gross proce
July 13, 2015	EX-99.1	Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock HAYWARD, Calif., July 8, 2015 /PRNewswire/ ? Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of
July 13, 2015	EX-1.1	3,333,334 Shares Anthera Pharmaceuticals, Inc. Common Stock ($0.001 Par Value) EQUITY UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 3,333,334 Shares Anthera Pharmaceuticals, Inc. Common Stock ($0.001 Par Value) EQUITY UNDERWRITING AGREEMENT July 9, 2015 Citigroup Global Markets Inc. Piper Jaffray & Co. As Representatives of the Several Underwriters c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Piper Jaffray & Co. 800 Nicollet Mall, Suite 1000 Minneapolis, Minnesota 55402
July 13, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commission
July 9, 2015	SC 13G	ANTH / Anthera Pharmaceuticals, Inc. / NEU RICHARD WATERMAN - SCHEDULE 13G Passive Investment SC 13G 1 d13614dsc13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Anthera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03674U201 (CUSIP Number) June 22, 2015** (Date of Event Which Requires Filing of this Statement) Check the appr
July 8, 2015	424B5	SUBJECT TO COMPLETION, DATED JULY 8, 2015 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-187780 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompany
May 21, 2015	EX-3.1	AMENDMENT TO AMENDED AND RESTATED BYLAWS ANTHERA PHARMACEUTICALS, INC. Unassociated Document Exhibit 3.1 AMENDMENT TO AMENDED AND RESTATED BYLAWS OF ANTHERA PHARMACEUTICALS, INC. WHEREAS, the Board of Directors of Anthera Pharmaceuticals, Inc. (the ?Corporation?) has determined that it is desirable and in the best interests of the Corporation and its stockholders to avoid the cost and disruption of multiforum litigation (i.e., litigation brought simultaneously in dif
May 21, 2015	8-K	Anthera Pharmaceuticals (Current Report/Significant Event) l5211508k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation
May 11, 2015	8-K	Anthera Pharmaceuticals (Current Report/Significant Event) j5111548k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation
May 11, 2015	EX-99.1	Anthera Pharmaceuticals Reports 2015 First Quarter and Operational Update ex991.htm Exhibit 99.1 Anthera Pharmaceuticals Reports 2015 First Quarter and Operational Update ? Completed Interim Analysis from Phase 3 Trial with Blisibimod for Systematic Lupus Erythematosus ? Completed Interim Analysis from Phase 2/3 Trial with Blisibimod for IgA Nephropathy ? Increased Cash Position by $43 Million Through Equity Investment by Zenyaku and Equity Offering Received $3 Million
May 11, 2015	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34637 ANTHERA P
April 9, 2015	DEFA14A	Anthera Pharmaceuticals 14A DEFA14A 1 f48150defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted
April 9, 2015	8-K	Anthera Pharmaceuticals (Current Report/Significant Event) n481508k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation
April 9, 2015	DEF 14A	Anthera Pharmaceuticals 14A DEF 14A 1 m48150def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ю Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement
March 20, 2015	424B5	5,555,556 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-187780 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2013) 5,555,556 Shares Common Stock We are offering 5,555,556 shares of our common stock. Our common stock is quoted on The NASDAQ Global Market under the symbol ?ANTH.? On March 18, 2015, the last reported sale price of our common stock on The NASDAQ Global Mar
March 20, 2015	EX-99.1	Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock HAYWARD, Calif., March 17, 2015 ? Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares
March 20, 2015	EX-99.2	Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock EX-99.2 Exhibit 99.2 Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock HAYWARD, Calif., March 18, 2015 ? Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 5,555,556 shares of its common stock, offered at a price of $4.50 per share. The Company estimates that the gross proceeds from the offering, before deductin
March 20, 2015	EX-1.1	5,555,556 Shares Anthera Pharmaceuticals, Inc. Common Stock ($0.001 Par Value) EQUITY UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 5,555,556 Shares Anthera Pharmaceuticals, Inc. Common Stock ($0.001 Par Value) EQUITY UNDERWRITING AGREEMENT March 18, 2015 Piper Jaffray & Co. As Representative of the Several Underwriters c/o Piper Jaffray & Co. 800 Nicollet Mall, Suite 1000 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Anthera Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), proposes to sel
March 20, 2015	8-K	Anthera Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commi
March 17, 2015	424B5	SUBJECT TO COMPLETION, DATED MARCH 17, 2015 424B5 1 d890283d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-187780 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus su
March 16, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34637 ANTHERA PHARMAC
March 16, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commissio
March 16, 2015	EX-10.33	WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT OF 1934. COLLABORATION AND LICENSE AGREEMENT Exhibit 10.33 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT OF 1934. COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agre
March 16, 2015	424B5	$10,300,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-187780 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2013) $10,300,000 Common Stock This prospectus supplement relates to the issuance and sale of up to $10,300,000 in shares of our common stock to Lincoln Park Capital Fund, LLC, or Lincoln Park, under a Purchase Agreement entered into on March 12, 2015, or the Pu
March 16, 2015	EX-99.1	Anthera Pharmaceuticals Reports 2014 Fourth Quarter and Fiscal Year Financial Results, Operational Update and Recent Event Highlights Exhibit 99.1 Anthera Pharmaceuticals Reports 2014 Fourth Quarter and Fiscal Year Financial Results, Operational Update and Recent Event Highlights - CHABLIS-SC enrollment on track for completion in mid-2015, interim analysis completed - Blisibimod autoimmune programs partnered with Zenyaku Kogyo Co., Ltd, Tokyo, Japan - Sollpura (liprotamase) manufacturing agreement executed with Patheon for clini
March 16, 2015	EX-10.31	ANTHERA PHARMACEUTICALS, INC. Deferred Compensation Election Form Exhibit 10.31 ANTHERA PHARMACEUTICALS, INC. Deferred Compensation Election Form I. Elective Deferral Percentages As specified below, I elect pursuant to the Deferred Compensation Agreement entered into by Anthera Pharmaceuticals, Inc. (the “Company”) and me as of the 23rd day of December, 2014 (the “Deferred Compensation Agreement”) to defer receipt of that percentage of my Eligible Compensation w
March 16, 2015	EX-10.36	SUBSCRIPTION AGREEMENT Exhibit 10.36 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Subscription”) is dated January 27, 2015, by and between the investor identified on the signature page hereto (the “Investor”) and Anthera Pharmaceuticals, Inc., a company incorporated and registered in the State of Delaware (the “Company”), whereby the parties agree as follows: 1. Subscription. (a) Investor agrees to buy and
March 16, 2015	EX-10.35	SUBSCRIPTION AGREEMENT Exhibit 10.35 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Subscription”) is dated January 27, 2015, by and between the investor identified on the signature page hereto (the “Investor”) and Anthera Pharmaceuticals, Inc., a company incorporated and registered in the State of Delaware (the “Company”). The Investor and the Company are parties to a Stock Purchase Agreement dated December
March 16, 2015	EX-10.23	Amendment No. 2 to License Agreement between Amgen Inc. and the Company, dated as of November 26, 2014(30) Exhibit 10.23 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT OF 1934. AMENDMENT NO. 2 TO LICENSE AGREEMENT This Amendment No. 2 to the Licens
March 16, 2015	EX-10.34	ANTHERA PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENT EX-10.34 5 ex1034.htm EXHIBIT 10.34 Exhibit 10.34 ANTHERA PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (the “Agreement”) is made and entered into as of December 11, 2014 (the “Effective Date”) by and between Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Zenyaku Kogyo Co., Ltd. (the “Purchaser”). Unless otherwise defined herein, all dolla
March 16, 2015	EX-10.1	PURCHASE AGREEMENT EX-10.1 3 d885257dex101.htm EX-10.1 Exhibit 10.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of March 12, 2015, by and between ANTHERA PHARMACEUTICALS, INC., a Delaware corporation, (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company w
March 16, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commissio
February 17, 2015	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 17, 2015	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Anthera Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03674U201 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
February 17, 2015	SC 13G/A	ANTH / Anthera Pharmaceuticals, Inc. / Flynn James E Passive Investment SC 13G/A 1 e613300sc13ga-anthera.htm SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * Anthera Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03674U201 (CUSIP Number) De
February 11, 2015	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation) (Commis
February 11, 2015	EX-99.2	Anthera Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Exhibit 99.2 Anthera Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements HAYWARD, Calif., Feb. 10, 2015 /PRNewswire/ - Anthera Pharmaceuticals (NASDAQ: ANTH) today announced that the company has received formal notification from the Nasdaq Stock Market ("Nasdaq"), indicating that the Company has regained compliance with Listing Rule 5450(b)(1)(A), which requires a minimum of $10,00
February 11, 2015	EX-99.1	Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for Systemic Lupus Erythematosus Exhibit 99.1 Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for Systemic Lupus Erythematosus - CHABLIS-SC1 study passes futility analysis and will continue to completion with an enhanced endpoint - Enrollment to be completed in 2015 with final data in Q3 2016 - Recent encouraging EMA feedback on BRIGHT-SC design to be incorporated prior to inter
February 9, 2015	SC 13G	ANTH / Anthera Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G 1 anth14in.htm CUSIP NO. 03674U201 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ANTHERA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03674U201 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Fili
February 3, 2015	SC 13G	ANTH / Anthera Pharmaceuticals, Inc. / Zenyaku Kogyo Co., Ltd. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Anthera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03674U201 (CUSIP Number) January 27, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
January 28, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2015 ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34637 20-1852016 (State or Other Jurisdiction of Incorporation)
January 28, 2015	424B5	3,216,646 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-187780 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2013) 3,216,646 Shares Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering an aggregate of 3,216,646 shares of our common stock directly to investors pursuant to subscription agreements we entered into with each o

ANTH / Anthera Pharmaceuticals, Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)